CHICAGO, IL (August 17, 2005) – PharmaNutrients, a leading research and development company and supplier of proprietary, science-based nutritional ingredients, has been awarded US Patent # 6,927,239 by the US Patent and Trademark Office. Entitled “Methods and Compositions for the Attenuation and/or Prevention of Stress Catabolic Response,” the patent uses PharmaNutrients’ proprietary CLA One® composition.
“During the course of our research at Penn State, we discovered CLA One® could reduce pro-inflammatory cytokines,” stated Dr. Susie Rockway, Director of Research and Development at PharmaNutrients and one of the lead inventors of the patent. “By modulating specific hormones and inflammatory molecules such as cytokines and eicosanoids before or at time of stress, CLA One® can influence those physiological processes associated with catabolic stress response.”
Recently, the FDA has withdrawn several pharmaceutical products due to dangerous side-effects; in fact, some cases have resulted in death. This has fueled a growing need for a safer, natural, scientifically validated alternative like CLA One®. Working by effectively reducing the expression of IL-1, IL-6, PGE2 and TNF, CLA One® thereby minimizes the stimulation or propagation of the stress response.
“Many acute and chronic illnesses are associated with a metabolic stress condition,” said Dr. Rockway. “I’m pleased that our patent will benefit in the treatment of these chronic conditions and that PharmaNutrients can play a positive role in promoting wellness.”
Mark Nottoli, President and founder of PharmaNutrients explained, “It has been PharmaNutrients’ strategy to create new technologies and applications for CLA beyond the initial role we identified in body composition. The new patent serves to strengthen and reinforce our patent portfolio supporting applications for cardiovascular health. This patent allows us to provide our customers with exclusive and unique, patent-protected products.”
About PharmaNutrients, Inc.:
Dedicated to creating products to enhance wellness, PharmaNutrients (www.pharmanutrients.com) supports research investigating fatty acids and soluble fibers. The company's activities encompass multiple technology platforms focused on creating solutions for obesity-related health issues including weight management, inflammation, diabetes and cardiovascular health. PharmaNutrients’ conjugated linoleic acid and chitosan-based products are used in a wide range of dietary supplements.
PharmaNutrients is recognized for creating Tonalin CLA, the first nutritional dietary supplement targeted at “Body Composition” and creating the “Fat Binding” category with Absorbitol brand chitosan complex. Since its de-merger with Natural ASA of Norway in 1999, PharmaNutrients has developed numerous patented applications for CLA beyond weight management.
Mark Nottoli, President